Off-Label Use of Antipsychotic Drugs Increasing

Jeannette Y. Wick, RPh, MBA, FASCP
Published Online: Thursday, March 22, 2012
Follow Pharmacy_Times:
The powerful drugs have been prescribed for a range of unapproved uses despite the risk of severe side effects.

 
Off-label prescription of powerful antipsychotic medications is growing increasingly common, raising serious safety concerns. According to a Washington Post article produced in collaboration with Kaiser Health News, the 11 drugs categorized as atypical antipsychotics have been prescribed to treat a range of illnesses for which they are not indicated, including sleep trouble, dementia, anxiety, attention deficit disorder, and behavioral problems in young children. The drugs can have severe side effects, including extreme weight gain, permanent facial tics, and increased risk of heart disease, type 2 diabetes, and—among the elderly—death.
 
Off-label atypical antipsychotic prescriptions more than doubled from 4.4 million in 1995 to 9 million in 2008, according to a study published in January 2011 in Pharmacoepidemiology and Drug Safety. Reasons for the increase include publicity around a new generation of antipsychotics, which are considered safer; hope that these drugs will work when others have failed; and direct-to-consumer advertising and increased marketing to physicians other than psychiatrists. Drug companies, which are prohibited from promoting or advertising off-label uses, have paid more than $2 billion in recent years to settle state and federal lawsuits alleging that they have illegally done so.
 
This increase in off-label use of antipsychotics is yet another reason for pharmacists to ensure they provide basic counseling when patients present prescriptions. It’s particularly important to ask patients if they know why they have been prescribed an atypical antipsychotic and to review possible side effects carefully.

Ms. Wick is a visiting professor at the University of Connecticut School of Pharmacy and a freelance writer from Virginia.

Related Articles
Rolee Pathak Das, PharmD, BCPS, clinical associate professor at Rutgers University Ernest Mario School of Pharmacy, talks about 1 of the most important issues facing pharmacy.
Kelli Kovak, industry expert on the pharmacy benefit manager industry and health care network designs, gives her perspective on how new health networks will benefit the business of pharmacy, how this will impact on patient choice, and how private pharmacies can stay connected and competitive.
This weekly video program highlights the latest in pharmacy news, product approvals, FDA rulings, and more.
A Chicago pharmacy owner has been indicted on charges of falsely billing $2.4 million for prescription drug claims.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$